AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) ("XBiotech") has completed payment to holders of its Common Stock of a previously announced dividend in the amount of USD$75,000,000.00. Based on the number of shares of Common Stock issued and outstanding on the record date for the dividend, each such holder received USD$2.47 per share on July 23, 2021. In the past 18 months, XBiotech's balance sheet strength has enabled the company to offer approximately USD$495 million in cash to shareholders by way of stock repurchase and dividend distribution. The financial strength of the Company owes to the successful development of a pipeline of True Human™ antibody drug

AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.'s (NASDAQ:XBIT) ("XBiotech") Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to an aggregate of $75 million, to holders of its common stock. This one-time, special dividend will be payable on July 23, 2021 to stockholders of record at the close of business on July 16, 2021. "XBiotech's proven ability to develop highly valued drug candidates, revenue from contract operations, judicious deployment of operating capital, absence of debt, and very significant emerging opportunities in our pipeline, has created the balance sheet flexibility that enables us to provide shareholder

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

4 - XBiotech Inc. (0001626878) (Issuer)

3 - XBiotech Inc. (0001626878) (Issuer)

10-Q - XBiotech Inc. (0001626878) (Filer)

10-Q - XBiotech Inc. (0001626878) (Filer)

8-K - XBiotech Inc. (0001626878) (Filer)

10-Q - XBiotech Inc. (0001626878) (Filer)

ARS - XBiotech Inc. (0001626878) (Filer)

DEFA14A - XBiotech Inc. (0001626878) (Filer)

DEF 14A - XBiotech Inc. (0001626878) (Filer)

10-K/A - XBiotech Inc. (0001626878) (Filer)

10-K/A - XBiotech Inc. (0001626878) (Filer)

10-K - XBiotech Inc. (0001626878) (Filer)

AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might po

AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- XBiotech Inc. today announced that it plans to expand it's campus headquarters with the construction of a new, state-of-the-art research and development facility. XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin 1st quarter 2024. The new four-story building, to be located close to the existing 46,000 ft2 manufacturing and R&D facility, will provide key infrastructure to support commercialization plans for the company's Natrunix rheumatology program. The new 46,000+ft2 facility will house clinical and medical operations, commercialization teams, and even incorporate we

AUSTIN, Texas, Nov. 14, 2023 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) today announced that Alan Kivitz M.D. is now Lead Investigator & Study Chairman for its clinical research program for Natrunix in Rheumatoid Arthritis. XBiotech believes Natrunix will be a breakthrough therapy for rheumatological diseases. The company has now enrolled about 33% of the 210 patients it is recruiting for a Phase II, Double-Blind, Placebo-Controlled, Randomized study, examining Natrunix in combination with methotrexate for the treatment of Rheumatoid Arthritis. There are presently about 25 clinical trial sites across the United States that are participating in the study. Dr. Kivitz, who is activ

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin. The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutrukin in healthy volunteers. Sequential dose escalation was conducted using three cohorts of subjects, each receiving a single intravenous infusion of either placebo or Hutrukin, with eight subjects i

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer. Natrunix is indistinguishable from a naturally occurring antibody present in a healthy human. Natrunix binds and neutralizes a potent substance, a so called cytokine known as interleukin-1a (IL-1a), that causes connective tissue breakdown, growth of new blood vessels, and recruitment of white blood cells. Malignant tumors, like pancreatic cancer, stimulate the body's production of IL-1a that i

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA). The primary endpoint of the Phase II is the American College of Rheumatology (ACR) 20% Response (ACR 20) rate at 12 weeks. Secondary and exploratory endpoints include ACR 50, ACR 70, numerical rating scale (NRS) for pain score, inflamed and painful joint counts, Health Assessment Questionnaire Disability Index (HAQ-DI), Routine Assess

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) today reports that the FDA's Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis. The randomized, double-blind, placebo-controlled, trial will examine the effectiveness of Natrunix to treat rheumatoid arthritis compared to placebo in subjects already receiving stable but inadequate treatment with methotrexate (MTX). A total of 210 patients will be randomly distributed in equal numbers into three groups: including two different Natrunix dosages and a placebo group. Change in disease severity will be assessed at multiple

AUSTIN, Texas, May 17, 2023 (GLOBE NEWSWIRE) -- Xbiotech Inc. (NASDAQ:XBIT) ("Xbiotech") announced today that it commenced a "modified Dutch auction" issuer tender offer to purchase up to $80,000,000 in value of its common shares, or such lesser number of common shares as are properly tendered and not properly withdrawn, at a price not greater than $4.00 nor less than $3.80 per common share, to the seller in cash, less any applicable withholding taxes and without interest (the "Offer"). The Offer is made upon the terms and subject to the conditions described in an offer to purchase dated May 17, 2023, the related letter of transmittal and the website established for purposes of effectuatin

AUSTIN, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) has enrolled the first subject in a randomized, open-label, placebo-controlled dose escalation clinical study to evaluate safety and pharmacokinetics of Hutrukin. Hutrukin is being developed as a novel treatment to reduce brain injury following ischemic stroke. There are more than 10 million ischemic strokes each year—the leading cause of death and morbidity in the world today. An ischemic stroke occurs when a blood clot forms in a blood vessel that supplies blood flow to brain. Blockage of blood flow to the brain results in brain injury, loss of brain function or death. Emergency use of "clot-busting" drugs or

AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much anticipated clinical study for XBiotech's candidate cancer treatment is being funded by the French National Cancer Institute (INCA). The study is headed by renown oncologists Dr. François Ghiringhelli and Dr. Come Lepage, Professor in Medical Oncology and Director of the INSERM research team at the Georges-Francois Leclerc Cancer Centre, and Professor at the Department of Gastroenterology and Digestive Oncology, Universit

Tuesday, XBiotech Inc (NASDAQ:XBIT) announced data from its Phase 1/Phase 2, 1-BETTER Study for advanced pancreatic cancer. The study examined the Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV)), which is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less-than-ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the company believes it might potentially also improve tolerability of the chemotherapy. The Phase 1 portion was a dose escalation study i

XBiotech (NASDAQ:XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen (ONIVYDE (ON) + 5-Fluorouracil (5FU) + Leucovorin (LV), a regimen that is already widely used for treating pancreatic cancer but is associated with difficult toxicities and less then ideal survival outcomes. Natrunix was being evaluated as an anti-cancer agent for use in cytotoxic chemotherapy combinations where the Company believes it might potentially also improve tolerability of the chemothe

Gainers MSP Recovery (NASDAQ:LIFW) shares rose 23.1% to $1.49 during Monday's pre-market session. The market value of their outstanding shares is at $21.4 million. 60 Degrees (NASDAQ:SXTP) stock moved upwards by 19.8% to $0.75. The market value of their outstanding shares is at $4.3 million. Telesis Bio (NASDAQ:TBIO) shares moved upwards by 17.61% to $0.37. The company's market cap stands at $11.1 million. scPharmaceuticals (NASDAQ:SCPH) stock increased by 16.47% to $6.22. The company's market cap stands at $223.0 million. OpGen (NASDAQ:OPGN) shares increased by 16.32% to $0.29. The company's market cap stands at $2.9 million. Bullfrog AI Hldgs (NASDAQ:BFRG) shares rose 15.95% to $5.67

XBiotech Inc. (NASDAQ:XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinical study has been enrolled. XBiotech discovered, manufactures, and is conducting this clinical study of Hutrukin. The primary objective of the Phase I study is to evaluate safety and pharmacokinetics of Hutrukin in healthy volunteers. Sequential dose escalation was conducted using three cohorts of subjects, each receiving a single intravenous infusion of either placebo or Hutrukin, with eight subjects in each cohort.Hutrukin is a candidate drug being deve

Gainers Akanda (NASDAQ:AKAN) shares increased by 13.5% to $0.63 during Tuesday's after-market session. Trading volume for this security closed at 668.1K, accounting for 276.8% of its average full-day volume over the last 100 days. The company's market cap stands at $2.4 million. VolitionRX (AMEX:VNRX) shares moved upwards by 11.99% to $1.4. The company's market cap stands at $109.3 million. Virpax Pharmaceuticals (NASDAQ:VRPX) shares moved upwards by 10.46% to $0.95. The market value of their outstanding shares is at $11.1 million. Cue Health (NASDAQ:HLTH) stock moved upwards by 8.19% to $0.55. The market value of their outstanding shares is at $83.7 million. Longeveron Inc. - Subscript

XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreatic cancer.   Natrunix is indistinguishable from a naturally occurring antibody present in a healthy human. Natrunix binds and neutralizes a potent substance, a so called cytokine known as interleukin-1a (IL-1a), that causes connective tissue breakdown, growth of new blood vessels, and recruitment of white blood cells. Malignant tumors, like pancreatic cancer, stimulate the body's production of IL-1a that induce tumor neovascularization, growth and spread

 XBiotech Inc. (NASDAQ:XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involved in pain and joint destruction in rheumatoid arthritis (RA).   The primary endpoint of the Phase II is the American College of Rheumatology (ACR) 20% Response (ACR 20) rate at 12 weeks. Secondary and exploratory endpoints include ACR 50, ACR 70, numerical rating scale (NRS) for pain score, inflamed and painful joint counts, Health Assessment Questionnaire Disability Index (HAQ-DI), Routine Assessment of Patient Index Data 3 (RAPID-3), Clinical D